AMGN Amgen Inc.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert A. Bradway
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AMGEN
SEC CIK
Corporate docs
IRS number
953540776
AMGN stock data
()
Calendar
29 Jul 20
7 Aug 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | 6.21B | 6.16B | 6.2B | 5.74B | |
| Net income | 1.8B | 1.83B | 1.7B | 1.97B | |
| Diluted EPS | 3.05 | 3.07 | 2.85 | 3.27 | |
| Net profit margin | 29.05% | 29.62% | 27.48% | 34.30% | |
| Operating income | 2.32B | 2.36B | 2.05B | 2.48B | |
| Net change in cash | -31M | 41M | 51M | -15M | |
| Cash on hand | 687M | 718M | 677M | 626M | |
| Cost of revenue | 1.49B | 1.51B | 1.25B | 1.04B |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 23.36B | 23.75B | 22.85B | 22.99B | |
| Net income | 7.84B | 8.39B | 1.98B | 7.72B | |
| Diluted EPS | 12.88 | 12.62 | 2.69 | 10.24 | |
| Net profit margin | 33.57% | 35.35% | 8.66% | 33.59% | |
| Operating income | 9.67B | 10.26B | 9.97B | 9.79B | |
| Net change in cash | 97M | 71M | 51M | 52M | |
| Cash on hand | 677M | 580M | 509M | 458M | |
| Cost of revenue | 4.36B | 4.1B | 4.07B | 4.16B |
Financial data from Amgen earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 3 Aug 20 | Nancy A. Grygiel | Common Stock | Payment of exercise | Dispose F | No | 244.67 | 290 | 70.95K | 11,026 |
| 1 Aug 20 | Esteban Santos | Common Stock | Payment of exercise | Dispose F | No | 244.67 | 2,165 | 529.71K | 44,376 |
| 31 Jul 20 | Kullman Ellen Jamison | Common Stock | Grant | Aquire A | No | 0 | 241.141 | 0 | 6,663.297 |
| 31 Jul 20 | Miles Amy E | Common Stock | Grant | Aquire A | No | 0 | 408 | 0 | 408 |
| 31 Jul 20 | Nancy A. Grygiel | Common Stock | Grant | Aquire A | No | 0 | 8,174 | 0 | 11,316 |
Institutional ownership Q1 2020
76.1% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1977 |
| Opened positions | 100 |
| Closed positions | 180 |
| Increased positions | 769 |
| Reduced positions | 846 |
13F shares |
Current |
|---|---|
| Total value | 90.22B |
| Total shares | 445.45M |
| Total puts | 4.78M |
| Total calls | 4.97M |
| Total put/call ratio | 1.0 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 49.65M | $10.06B |
| BLK BlackRock | 46.46M | $9.42B |
| Capital Research Global Investors | 33.11M | $6.71B |
| STT State Street | 26.21M | $5.31B |
| Primecap Management | 18.48M | $3.75B |
| FMR | 17.65M | $3.58B |
| Geode Capital Management | 10.12M | $2.05B |
| NTRS Northern Trust | 7.98M | $1.62B |
| BAC Bank of America | 7.8M | $1.58B |
| MS Morgan Stanley | 7.26M | $1.47B |
Financial report summary
?Competition
Scios • Poniard Pharmaceuticals • Imclone Systems • Ir Biosciences • Celgene • ImmunoCellular Therapeutics • Novelion Therapeutics • Spectrum Pharmaceuticals • Medimmune • GenaeraManagement Discussion
- Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products’ significant competitors, see Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition.
- The increase in ENBREL sales for 2019 was driven primarily by favorable impacts from changes in accounting estimates of sales deductions and an increase in net selling price, offset partially by lower unit demand. For 2020, we expect the trend of lower unit demand to continue.
- The decrease in ENBREL sales for 2018 was driven primarily by lower unit demand and net selling price.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
acute, alfa, amplify, AstraZeneca, baseline, bone, border, called, cardiac, clarification, clear, cohort, concurrently, contractile, count, daily, deplete, diminish, diminished, discourage, dozen, ebb, ejection, Emcure, epoetin, febrile, fell, fraction, granulocyte, heart, Heritage, HFrEF, intermediate, intermittent, Italy, kit, LP, lung, mecarbil, mg, myosin, myotrope, NCCN, neutropenia, newer, omecamtiv, Onpro, onset, opened, pace, payoff, pendency, placebo, plaque, Pool, preclude, prioritize, pro, prolia®, rata, reallocation, reconsideration, reevaluate, reimpose, reinstate, reinstatement, relaxation, respiratory, resume, resumed, resurgence, rheumatology, score, Spain, sPGA, static, statistically, stemming, stopped, stricter, syndrome, therefrom, timeline, unclear
Removed:
adding, affiliated, banc, BBB, BioPharma, brought, challenge, closely, david, declined, decreased, denied, en, established, high, Hospira, impacted, institute, inter, jury, launched, manufacture, meline, moving, multidistrict, opinion, panel, periodically, petition, Pfizer, preliminary, purposed, rehearing, requesting, restructuring, scheduled, separate, sheet, Teva, unfavorable
Financial reports
10-Q
2020 Q2
Quarterly report
29 Jul 20
10-Q
2020 Q1
Quarterly report
1 May 20
10-K/A
2019 FY
Annual report (amended)
13 Feb 20
10-K
2019 FY
Annual report
12 Feb 20
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
13 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
27 Jul 18
Current reports
8-K
Other Events
30 Jul 20
8-K
Amgen Reports Second Quarter 2020 Financial Results
28 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20
8-K
Departure of Directors or Certain Officers
23 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
20 May 20
8-K
Entry into a Material Definitive Agreement
6 May 20
8-K
Amgen Reports First Quarter 2020 Financial Results
30 Apr 20
8-K
Amgen Update RegardingCOVID-19 For Media
31 Mar 20
8-K
Entry into a Material Definitive Agreement
21 Feb 20
8-K
Amgen Reports Fourth Quarter and Full Year 2019 Financial Results
30 Jan 20
Registration and prospectus
424B2
Prospectus for primary offering
6 May 20
FWP
Free writing prospectus
5 May 20
424B3
Prospectus supplement
4 May 20
424B2
Prospectus for primary offering
20 Feb 20
FWP
Free writing prospectus
18 Feb 20
424B3
Prospectus supplement
18 Feb 20
S-3ASR
Automatic shelf registration
10 Feb 20
SC TO-I/A
Issuer tender offer statement (amended)
8 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
6 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
26 Feb 18
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
PX14A6G
Letter to shareholders
15 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Apr 20
DEF 14A
Definitive proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
13 May 19
DEFA14A
Additional proxy soliciting materials
2 May 19
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEFA14A
Additional proxy soliciting materials
22 Apr 19
Other
CT ORDER
Confidential treatment order
24 Oct 19
CT ORDER
Confidential treatment order
3 Jun 19
CT ORDER
Confidential treatment order
30 May 18
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
4 Dec 17
CT ORDER
Confidential treatment order
8 Sep 17
CT ORDER
Confidential treatment order
15 Aug 17
CT ORDER
Confidential treatment order
26 May 17
CT ORDER
Confidential treatment order
8 May 17
CT ORDER
Confidential treatment order
6 Mar 17
Ownership
4
AMGEN / Esteban Santos ownership change
3 Aug 20
4
AMGEN / Nancy A. Grygiel ownership change
3 Aug 20
4
AMGEN / AMY E MILES ownership change
3 Aug 20
4
AMGEN / Ellen Jamison Kullman ownership change
3 Aug 20
3
AMGEN / Linda H. Louie ownership change
29 Jul 20
3
AMGEN / AMY E MILES ownership change
27 Jul 20
4
AMGEN / RONALD D SUGAR ownership change
22 Jul 20
4
Change in insider ownership
16 Jul 20
SC 13D/A
BeiGene / AMGEN ownership change
16 Jul 20
3
AMGEN / Nancy A. Grygiel ownership change
2 Jul 20
Patents
APP
Utility
Macrocyclic Compounds That Inhibit MCL-1 Protein
6 Aug 20
Inventors: Sean P. BROWN, Yunxiao LI, Paul E. HARRINGTON, Brian Alan LANMAN, Jonathan D. LOW, Ana Elena MINATTI, Vu Van MA, Kexue LI
APP
Utility
Methods and Systems of Performing an Assay
6 Aug 20
Methods and systems of performing an assay.
GRANT
Utility
Alkynyl dihydroquinoline sulfonamide compounds
4 Aug 20
Inventors: Matthew Weiss, Thomas Dineen, Karina R. Vaida
APP
Utility
Insertion Mechanism and Method of Inserting a Needle of a Drug Delivery Device
30 Jul 20
An insertion mechanism for a drug delivery device.
APP
Utility
KIF18A Inhibitors
30 Jul 20
Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, James Alexander BROWN, Michael J. FROHN, Jian Jeffrey CHEN, Kexue LI, Qingyian LIU, Jonathan Dante LOW, Vu MA, Liping H. PETTUS, Mary Catherine WALTON, Ana Elena MINATTI, Matthew Paul BOURBEAU, Lei JIA